The design of clinical trials in psoriasis: Lessons for clinical practice

被引:9
作者
Feldman, SR [1 ]
机构
[1] Wake Forest Univ, Dept Dermatol, Winston Salem, NC 27157 USA
关键词
D O I
10.1016/S0190-9622(03)01137-X
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Understanding the process by which drugs are approved gives clinicians a better understanding of the medications they prescribe and how these medications are best used to care for patients. The development of new drugs in the United States proceeds through a series of studies culminating in well-designed, large-scale human trials. These studies result from a coordinated collaboration between industry and the Food and Drug Administration (FDA). The results of these studies determine whether drugs are approved for use or not. They also determine the labeling and marketing of products and guide (but do not fully determine) physicians' use of the drug. This article follows a hypothetical drug for use-in psoriasis through the approval process, in order to illustrate the process and its implications for clinical practice.
引用
收藏
页码:S62 / S65
页数:4
相关论文
共 7 条
[1]   The roles of the pharmaceutical industry and drug development in dermatology and dermatologic health care [J].
Altman, DJ .
DERMATOLOGIC CLINICS, 2000, 18 (02) :287-+
[2]   SEVERE PSORIASIS - ORAL THERAPY WITH A NEW RETINOID [J].
FREDRIKSSON, T ;
PETTERSSON, U .
DERMATOLOGICA, 1978, 157 (04) :238-244
[3]   SIDE-EFFECT PROFILE OF ACITRETIN THERAPY IN PSORIASIS [J].
GUPTA, AK ;
GOLDFARB, MT ;
ELLIS, CN ;
VOORHEES, JJ .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1989, 20 (06) :1088-1093
[4]   Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? [J].
Krueger, GG ;
Feldman, SR ;
Camisa, C ;
Duvic, M ;
Elder, JT ;
Gottlieb, AB ;
Koo, J ;
Krueger, JG ;
Lebwohl, M ;
Lowe, N ;
Menter, A ;
Morison, WL ;
Prystowsky, JH ;
Shupack, JL ;
Taylor, JR ;
Weinstein, GD ;
Barton, TL ;
Rolstad, T ;
Day, RM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (02) :281-285
[5]   Acitretin in combination with UVB or PUVA [J].
Lebwohl, M .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 41 (03) :S22-S24
[6]  
Lipsky M S, 2001, J Am Board Fam Pract, V14, P362
[7]  
*PENL, PENL PROD INF